| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8207125 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
| US7232818 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
| US8207297 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
| US7417042 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Jul, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207126 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
| US7491704 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
| US8129346 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
| US8207127 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
| US7737112 | ONYX PHARMS AMGEN | Composition for enzyme inhibition |
Dec, 2027
(3 years from now) | |
| USRE47954 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(5 years from now) | |
| US9511109 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(5 years from now) | |
| US9493582 | ONYX PHARMS AMGEN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
Kyprolis is owned by Onyx Pharms Amgen.
Kyprolis contains Carfilzomib.
Kyprolis has a total of 12 drug patents out of which 0 drug patents have expired.
Kyprolis was authorised for market use on 07 June, 2018.
Kyprolis is available in powder;intravenous dosage forms.
Kyprolis can be used as kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy, use in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy, kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
Drug patent challenges can be filed against Kyprolis from 20 July, 2016.
The generics of Kyprolis are possible to be released after 27 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; Use in combination with lenalidomide ...
Dosage: POWDER;INTRAVENOUS
KYPROLIS family patents
